阿德福韦酯联合拉米夫定治疗乙型肝炎肝硬化患者血清细胞因子水平的变化

doi:10.3969/j.issn.1672-5069.2017.02.029

Abstract

He Lulu， Chen Fei.. Changes of serum levels of TGF-β1 and IL-8 in patients with hepatitis B viral infection-induced liver cirrhosis receiving adefovir ester combined lamivudine therapy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 234-235.

References

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2015年版）.实用肝脏病杂志，2016，19（3）：Ⅴ-ⅩⅩⅢ.
[2] 陈瑞红.拉米夫定联合阿德福韦酯治疗老年失代偿期乙型肝炎后肝硬化的疗效分析.中国现代药物应用，2016，10（3）:167-168.
[3] 翟厚峰，姚茜，何倩，等. 初始拉米夫定联合阿德福韦酯与恩替卡韦单药治疗乙型肝炎肝硬化患者疗效对比.中国实用医药，2016，11（4）:131-132.
[4] 王和木，吴学锋，温梅儿.拉米夫定联合阿德福韦酯对活动性乙型肝炎肝硬化长期治疗的疗效.蛇志，2016，28（1）:54-55.
[5] 郑高见.活动性代偿期乙型肝炎肝硬化采用阿德福韦酯治疗的临床价值探析.数理医药学杂志，2016，29（1）:90-91.
[6] 郭玉刚.拉米夫定联合阿德福韦酯治疗老年失代偿期乙型肝炎后肝硬化的临床疗效探讨.中外医疗，2016，35（8）:113-114.
[7] 罗晓蓉，宋长龙.乙型肝炎肝硬化患者使用阿德福韦酯配合拉米夫定治疗的效果分析.海峡药学，2016，28（1）:132-134.
[8] 曾民民.乙型肝炎肝硬化失代偿期行拉米夫定联合阿德福韦酯治疗的效果与安全性观察.当代医学，2016，22（2）:150-151.
[9] 胡倩，鲁海峰.阿德福韦酯联合拉米夫定治疗乙型肝炎肝硬化的临床疗效观察.中国现代医生，2015，53（32）:108-111.
[10] 彭小华，高美金.拉米夫定与阿德福韦酯联合治疗乙型肝炎肝硬化实效性分析.中华全科医学，2015，13（6）:929-931.
[11] 严井泉.阿德福韦酯联合拉米夫定治疗失代偿期乙型肝炎肝硬化临床研究.中国处方药，2016，14（5）:54-55.
[12] 李小溪，李波，李筱涵，等.肝纤维化相关细胞因子的血清学检测对慢性乙型肝炎肝纤维化进程的诊断价值.现代生物医学进展，2014，14（16）:3109-3111.

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[8]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[9]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[10]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[11]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[12]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[13]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[14]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[15]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.

Changes of serum levels of TGF-β1 and IL-8 in patients with hepatitis B viral infection-induced liver cirrhosis receiving adefovir ester combined lamivudine therapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments